XERS Xeris Biopharma Holdings, Inc.
FY2025 10-K
Xeris Biopharma Holdings, Inc. (XERS) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Commercial-stage biopharma focused on therapies for chronic endocrine and neurological diseases in the U.S., with three commercial products: Recorlev, Gvoke, Keveyis
- • Phase 3-ready XP-8121: once-weekly subcutaneous levothyroxine injection leveraging proprietary XeriSol tech, planned Phase 3 start in 2026
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in the provided MD&A section
- • Financing cash inflow $11.4M in 2025 vs $36.2M in 2024; driven by $20.7M stock awards and $10.9M stock repurchases
Risk Factors
- • Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
- • Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility
Get deeper insights on Xeris Biopharma Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.